In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research ...

There's been a notable change in appetite for Arcus Biosciences, Inc. ( NYSE:RCUS ) shares in the week since its ...

Fintel reports that on February 26, 2025, HC Wainwright & Co. upgraded their outlook for Arcus Biosciences (NYSE:RCUS) from ...

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its ...

H.C. Wainwright analyst Emily Bodnar upgraded Arcus Biosciences (RCUS) to Buy from Neutral with a price target of $24, up from $18. The ARC-20 ...

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to loss of $1.08 per share a year ago. These ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...

Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a ...

Arcus Biosciences, Inc. (NYSE: RCUS) announced on February 18, 2025, that it has entered into an underwriting agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC for the offering, issuance ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...